FOSUN HEALTH Logo

Type 2 Diabetes Treatment

catalogue

Type 2 Diabetes Treatment

Type 2 Diabetes Treatment

Treatment in type 2 diabetes has a foundation and then layers, and the foundation is not a medicine. This page sets out what that foundation is, why metformin comes first, what each class is chosen for beyond its effect on the number, when insulin enters the plan and why that is not a failure, and — the part people are least often told — how hypoglycaemia is recognised and treated, and which medicines cause it and which do not.

The foundation: what comes before the medicine

Everything else on this page is built on this section, and it is the section most often skipped. Medicine is added to a foundation; it does not replace one.

  • Structured education delivered properly rather than as a leaflet. People who understand what the numbers mean make different decisions at three in the morning and during an illness, which is where outcomes are decided.
  • Food a person can live with for years. There is no single diet; what matters is consistency rather than perfection — vegetables and fibre, whole grains in place of refined ones, fewer sugary drinks and less ultra-processed food, portions that match the day.
  • Activity in two forms: moderate aerobic work across the week, and resistance work twice a week. Muscle clears glucose without insulin having to work harder.
  • Weight, where there is weight to lose. Fat around the abdomen and in the liver drives resistance hardest, and losing part of it changes the picture measurably.
  • Sleep, routinely omitted. Shortened sleep and untreated sleep apnoea both worsen resistance, and treating the second often improves glucose more than another tablet would.
  • Not smoking, which stacks its own vascular risk onto the risk already present.
  • Blood pressure and lipids, treated to agreed targets — a section of their own below, because they are not a footnote.

These are the parts that determine long-term risk, they work alongside medicine rather than instead of it, and they are reviewed rather than prescribed once. What they look like day to day is on the living-with-it page.

Metformin — why it comes first

Metformin has been the usual first medicine for a long time, and it holds that place for reasons that have very little to do with fashion. It reduces the glucose the liver releases into the bloodstream and it improves how well insulin works in the tissues. It does not cause hypoglycaemia when used on its own, it does not cause weight gain, and there is more experience with it, in more people, over more years, than with anything else in the field.

How it is taken matters more than with most medicines. It is started low and increased gradually, because the stomach side effects that make people stop it are largely avoided that way, and it is taken with food. If it still upsets the stomach, that is a reason to discuss the dose or the formulation, not to conclude it does not suit you.

Two longer-term points. Vitamin B12 can fall with years of use and is worth measuring periodically. And kidney function decides whether metformin continues and at what dose: as filtration falls the dose is reviewed, and it is paused during severe illness with dehydration or before certain contrast procedures, then restarted once eating and drinking normally. A pause during illness is a safety measure, not a sign the medicine has stopped suiting you.

It is usually continued rather than replaced when other medicines are added — which is worth knowing, because people often assume the older medicine is dropped as the newer one arrives.

The other classes, and what each is chosen for

The choice of a second or third medicine is not made by how high the number is. It is made by the picture: whether the heart or kidneys need protecting, what the weight is doing, how much hypoglycaemia risk is acceptable, what kidney function allows, and what is available where the person lives. Suitability, availability and dose are assessed by the clinician; what follows names classes and reasons, not prescriptions.

The classes, what each does, and what it is chosen for
Class What it does Why it is chosen Hypoglycaemia on its own
SGLT2 inhibitors Let the kidney pass glucose out into the urine For heart and kidney protection as a class, which is why they are used in people whose glucose is already near target Low
GLP-1 receptor agonists Increase insulin when glucose is high, slow the stomach, reduce appetite For glucose and weight together, and for cardiovascular benefit as a class where vascular disease is established Low
DPP-4 inhibitors Prolong the body's own incretin effect Modest effect, well tolerated, weight-neutral — chosen where simplicity matters more than magnitude Low
Sulfonylureas Stimulate the pancreas to release more insulin Effective, long-established and inexpensive, and widely available Yes — a real risk, and the dose matters
Thiazolidinediones Improve insulin sensitivity in the tissues Where insulin resistance dominates, taking the accompanying cautions into account Low
Insulin Replaces what the body no longer makes enough of When beta-cell output is insufficient, and there is no ceiling on how well it works Yes — the main cause, and the reason for the next section

Two deserve expansion. SGLT2 inhibitors make the kidney pass glucose out, and three things follow: genital thrush is more common and is managed rather than tolerated; water is lost with the glucose, so hydration matters during illness and in heat; and rarely, ketones build up while the reading is not especially high — so nausea, vomiting, abdominal pain or breathlessness in someone taking one needs assessment whatever the meter shows. GLP-1 receptor agonists are injected and work on appetite as well as glucose, which is why they appear where weight is the dominant problem; nausea early on is the main drawback, and there are specific reasons they are not used in some people.

Sulfonylureas are still prescribed despite causing hypoglycaemia because they work, they are inexpensive and they are available almost everywhere. The trade-off is acceptable in some people and not in others — in someone who drives for a living, lives alone, or has already had a serious low, it usually is not.

Insulin — when it enters the plan, and why it is not a failure

Insulin production falls gradually across the years in type 2 diabetes. That is the ordinary course of the condition rather than a complication of it, and it is the reason a person who managed well on tablets for a decade may eventually need it. Insulin is the most effective medicine available for lowering glucose, and there is no ceiling on how well it works.

Two forms are used, doing different jobs. Basal insulin is a long-acting background dose covering what the liver releases between meals and overnight. Mealtime insulin is rapid-acting, taken with food. Many start with basal alone, adjusted against the fasting reading; mealtime doses are added where the pattern shows the problem is after eating. Which is used follows the monitoring rather than the HbA1c alone.

Insulin can also be given by pump — continuous subcutaneous insulin infusion — delivering a steady basal rate and mealtime doses from one device. It is used in selected people after training, and it is not a convenience: it requires more engagement with the condition, not less. Our endocrinology department holds Medtronic insulin pumps and provides the training.

The practical parts are worth stating because nobody teaches them unless asked. Injection sites must be rotated, because repeated use of one spot builds fatty lumps that absorb insulin unpredictably. Insulin kept too hot or frozen stops working. Dose adjustment for time zones, missed meals and illness belongs in the written plan rather than in improvisation, and driving requires a check beforehand and glucose in the vehicle.

What should be said plainly is that insulin in type 2 diabetes is a stage and not a verdict. The belief that needing it means something went wrong is why people delay it for years, and delaying it means more time with glucose well above target.

Hypoglycaemia: recognition, treatment and what to change

This section exists because of a sentence rarely said out loud: low glucose is caused by treatment, not by the disease. It is not a feature of type 2 diabetes; it is a feature of insulin and of sulfonylureas. Metformin, GLP-1 receptor agonists and SGLT2 inhibitors, used alone, rarely cause it. Someone told only that they have diabetes may worry about lows they cannot have; someone starting insulin and not told may treat the first one as a bad day.

The signs come in two groups, and the second is the one people miss. The first is the body's alarm: shakiness, sweating, sudden hunger, palpitations, anxiety, pallor. The second is the brain running short: difficulty concentrating, confusion, slurred speech, odd behaviour, drowsiness, and in a severe episode a seizure. Anyone who has had repeated lows may lose the alarm signs entirely — which is why recurrent lows are treated by reviewing the regimen rather than by advice about carrying sugar.

The treatment is the fifteen-gram rule, worth knowing rather than looking up. Take roughly fifteen grams of fast-acting carbohydrate — a small glass of fruit juice, a few glucose tablets, sugar in water; not chocolate, a biscuit or milk, because fat and protein slow absorption. Wait fifteen minutes and measure again; if still low, repeat once. Then eat something longer-acting if the next meal is not imminent. If the person is drowsy, confused or unable to swallow, put nothing in their mouth: that is a glucagon injection where prescribed, and an emergency call.

Three further points belong to any plan including insulin or a sulfonylurea. Every low should be reported, because a pattern of lows is what tells a clinician to loosen the target or change the medicine — and awareness recovers when lows stop. Night-time lows are the ones nobody measures, which is what continuous or flash monitoring finds and finger-pricks do not. And driving or operating machinery requires a check beforehand with carbohydrate within reach.

After a low there are three possible answers — the dose was too high for what was eaten or done, the timing was wrong, or the target was too tight. All three are fixable, and none is fixed by eating more and saying nothing. The sick-day rules that go with this are on the day-to-day page.

Blood pressure and lipids — the part that matters as much as glucose

Of everything that reduces long-term risk here, treating blood pressure and cholesterol usually does more than any further lowering of glucose. That is not an opinion about which medicine is better; it is a statement about where the risk sits once the diagnosis is made.

Blood pressure is measured at every visit and treated to a target agreed for the person, usually tighter than for someone without diabetes. Medicines acting on the renin–angiotensin system are used particularly often, especially where albumin is leaking into the urine or kidney protection is part of the aim; others are chosen for age, ethnicity and tolerability. Home readings matter more than clinic readings, because one surgery reading is a poor guide to the year.

Lipids are treated with a statin at an intensity matched to vascular risk, with additional medicines where the target is not reached. The goal is a level rather than a number on a chart, reassessed alongside the rest of the picture.

The rest of the plan: not smoking, the largest removable risk; vaccination as advised, because infection destabilises everything else; dental care, since gum disease and glucose affect each other in both directions; and treatment of sleep apnoea, which improves blood pressure and glucose together.

All of this is assessed and prescribed by your clinician. What this page asks is narrower: that blood pressure and lipids be treated as part of the diabetes plan, and that the targets be written down where you can check them.

What our endocrinology department does here

Within our hospital, the assessment and the ongoing plan are carried by the endocrinology department. Its diabetes subspecialty sits alongside four others — thyroid disease, obesity and metabolic disease, pituitary, adrenal and gonadal disease, and bone metabolism — so the conditions that travel with diabetes are seen in one department.

The department holds flash continuous glucose scanning and Medtronic insulin pumps, with the training that goes with both, and a fundus screening device, a diabetic foot screening device, a lipid analyser and ultrasound for the screening described on the monitoring page. Thyroid nodule aspiration is performed where a nodule needs characterising early.

On the complications side, its published work on people with combined diabetes and obesity includes early coronary screening, multidisciplinary lower-limb arterial intervention for diabetic foot disease, and systematic treatment of diabetic retinopathy with our ophthalmologists. A medical weight-loss clinic builds weight programmes from an endocrine and metabolic standpoint, with attention to reducing the chance of regaining weight.

The complications themselves have their own pages, and this guide points to them rather than duplicating them: diabetic nephropathy, diabetic retinopathy and diabetic foot ulcers. The department's named specialists include Dr Jiang Yiwen, chief physician, whose published interests cover thyroid disease and diabetes with its complications, and Dr Li Meng, whose published interests include the acute and chronic complications of diabetes, thyroid disease, secondary hypertension, hyperuricaemia, gouty arthritis, adrenal and pituitary disease, and obesity.

Nothing on this page is a promise. Type 2 diabetes is managed rather than cured, and what treatment offers is a lower risk of the things that otherwise happen over twenty years, an agreed target, and a plan reviewed as the picture changes.

Frequently Asked Questions

Will I be on medicine for life?

Probably, and it is better understood as a plan that changes than as a life sentence. Type 2 diabetes is progressive: resistance persists and beta-cell output falls gradually, so most people need more treatment at sixty than they did at forty. What changes is which medicines and how many. A plan can also be simplified — when weight falls substantially, when another medicine stops, or when a target has been loosened for good reason — and it is reviewed at each visit rather than left as it was.

Is metformin safe to take for years?

It has the longest safety record of any medicine used in this condition, and most people take it for decades. The side effects that matter are stomach-related and largely avoided by starting low, increasing slowly and taking it with food. The long-term point people ask about is vitamin B12, which can fall with prolonged use and is worth checking periodically. Kidney function decides whether it continues at the same dose, and it is paused temporarily in situations such as severe dehydration or certain contrast procedures — decisions taken by your clinician.

If I need insulin, have I failed?

No, and the belief that you have is one of the more damaging things about this condition. Insulin production falls gradually over the years in type 2 diabetes; needing what the body no longer makes is the condition taking its ordinary course, not a verdict on anything. Insulin is also the most effective medicine for lowering glucose. What it adds is a requirement: anyone using it needs to know how to recognise and treat a low, what to do when ill, and what to do before driving.

Can the treatment be reduced if my weight and glucose improve?

Sometimes, and the decision belongs to a review rather than to a good month. A substantial and sustained fall in weight can improve resistance enough that less medicine is needed, and a plan that can be simplified should be. But reducing treatment on the strength of a few good readings is the commonest way to lose control that took months to achieve, and medicines protecting the heart or kidney continue for that reason whether or not the number needs them. What your clinician looks at is the trend, why each medicine is there, and what happens if the weight returns.

Get the plan matched to your picture, and the target written down

Send your current medicines with doses, your latest HbA1c and glucose results with dates, blood pressure readings taken at home, kidney and lipid results, your weight history, and a note of any low you have had and what you were doing at the time. Our team will return a written opinion on whether the medicines match your heart and kidney picture, whether the target is right for you, and what the plan is missing.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*